版本:
中国

BRIEF-Omeros says FDA grants breakthrough therapy designation to OMS721 for treatment of IgA Nephropathy

June 13 Omeros Corp:

* FDA grants breakthrough therapy designation to Omeros’ MASP-2 inhibitor OMS721 for the treatment of IgA Nephropathy

* Omeros' second phase 3 clinical program for OMS721 slated to begin this year

* ‍OMS721 is also being evaluated in a phase 3 clinical program for atypical hemolytic uremic syndrome​

* ‍OMS721 also being evaluated in a phase 2 clinical program for hematopoietic stem cell transplant-associated thrombotic microangiopathy​

* One or more additional OMS721 phase 3 clinical programs planned to initiate this year in IgA nephropathy, stem cell transplant-associated TMA

* Following discussions with FDA and European Medicines Agency, phase 3 program for OMS721 in atypical hemolytic uremic syndrome is in progress

* Preparing to initiate manufacturing scale-up of its MASP-3 antibodies in advance of clinical trials

* Omeros also expects to commercialize OMS721 for one or more therapeutic indications as a subcutaneous injection

* Preliminary clinical evidence indicating that drug may demonstrate "substantial" improvement over existing therapies is required Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐